Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3490523 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL2840040 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL3488076 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL2841053 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL3490529 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL3238670 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL2879443 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL19617734 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL16371200 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL3487909 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-29 | — | — | US | claimed |
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | US | claimed |
| WO-2010030739-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | claimed |
| WO-2010030730-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | claimed |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | claimed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | KYOWA KIRIN CO., LTD. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | KYOWA KIRIN CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| EP-3662913-A1 | NUCLEIC-ACID-CONTAINING LIPID NANOPARTICLES | Kyowa Kirin Co., Ltd. (JP) | 2020-06-10 | — | — | EP | disclosed |
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2010030739-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030730-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | ALDH1A1 1734/4885CNR1 3492/4885CNR2 3231/4885 |
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | ALDH1A1 4724/4885CNR1 3144/4885CNR2 2239/4885 |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | ALDH1A1 1734/4885CNR1 3492/4885CNR2 3231/4885 |
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | LIPA, LIPC, PNLIP | ALDH1A1 354/4885CNR1 3755/4885CNR2 3991/4885 |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | LIPA, LIPC, PNLIP | ALDH1A1 354/4885CNR1 3755/4885CNR2 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.